Uses of Gamma Irradiated Amniotic Membrane as an Alternative Method in Psoriasis Treatment

Not Applicable

Completed

• Conditions: Psoriasis

• Registration Number: NCT03440541
• Lead Sponsor: Egyptian Atomic Energy Authority

Brief Summary

Using of human amniotic membrane extra-cellular matrix as a topical treatment for improving Psoriasis Area and Severity Index (PASI).

Detailed Description

Human amniotic membrane extra-cellular matrix was purchased from National center for radiation research and technology, Egypt, under commercial name REGE pro gel.

Study Timeline

• Study Start: 2015-08-04
• Primary Completion: 2016-02-13
• Study Completion: 2016-04-08
• Study First Submitted: 2017-11-29
• Study First Submitted QC: 2018-02-19
• Study First Posted: 2018-02-22
• Status Verified: 2019-06
• Last Update Submitted: 2019-06-26
• Last Update Posted: 2019-06-27

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 22

Inclusion Criteria

• patients have psoriasis lesion

Exclusion Criteria

• must stop other line of treatment

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Primary Outcome Measures

Name	Time	Method
Histopathological improvement	6 weeks	Two biopsies were taken from each patient before and at the end of the treatment. It was noted that all histological signs as munro's microabscess and the elongation of rete ridges were absent.
Scaling size decrement	2 weeks	REGE pro gel decreased scaling size in patients with sever scales to moderate scale within two weeks, scaling size decrement from moderate to mild within two weeks, and from mild to complete curing within two weeks

Secondary Outcome Measures

Name	Time	Method
Erythema disappearing	4-6 weeks	REGE pro gel gradually decreased erythema in patients within 4-6 weeks, these data were collected from applied patients by questionnaire.

Trial Locations

Locations (1)

Amniotic tissue lab; 🇪🇬 Cairo, Egypt